FDA Drug recall D-0621-2020
EXPAREL, Bupivicaine Liposome Injectable Suspension, 1.3%, 266 mg/20 mL (13 mg/mL), Sterile, 20 mL vial, Rx only, Manufactured by: Pacira P…
- FDA Drug
- Class II
- terminated
- Published 2019-12-11
On 2019-12-11 the FDA classified a Class II recall of EXPAREL, Bupivicaine Liposome Injectable Suspension, 1.3%, 266 mg/20 mL (13 mg/mL), Sterile, 20 mL vial, Rx only, Manufactured by: Pacira P… by Pacira Pharmaceuticals, citing sub Potent Drug: Out of Specification (OOS).
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0621-2020 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2019-11-21 |
| Published | 2019-12-11 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Pacira Pharmaceuticals |
| Distribution | US |
Product
EXPAREL, Bupivicaine Liposome Injectable Suspension, 1.3%, 266 mg/20 mL (13 mg/mL), Sterile, 20 mL vial, Rx only, Manufactured by: Pacira Pharmaceuticals, Inc. San Diego, CA 92121. NDC: 65250-266-20,
Reason
Sub Potent Drug: Out of Specification (OOS)
Identifiers
| ndc | 65250-133-10 |
|---|---|
| ndc | 65250-133-09 |
| ndc | 65250-133-04 |
| ndc | 65250-266-20 |
| ndc | 65250-266-09 |
| ndc | 65250-266-04 |
| code_info | Pacira Lot #: 19-5002, Patheon manufacturer Lot #: 098214; Exp. Date: Dec 2019 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0621-2020%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.